Summary
Soleno Therapeutics, Inc. (SLNO) Q3 2025 Earnings Call Transcript
Soleno Therapeutics, Inc. ( SLNO ) Q3 2025 Earnings Call November 4, 2025 4:30 PM EST Company Participants Anish Bhatnagar - Chairman, President, CEO & COO Meredith Manning - Chief Commercial Officer James MacKaness - CFO & Compliance Officer Conference Call Participants Brian Ritchie - Lifesci Advisors, LLC Kyuwon Choi - Goldman Sachs Group, Inc., Research Division Tyler Van Buren - TD Cowen, Research Division Moritz Reiterer - Guggenheim Securities, LLC, Research Division Rick Miller - Cantor Fitzgerald & Co., Research Division Yasmeen Rahimi - Piper Sandler & Co., Research Division Leland Gershell - Oppenheimer & Co. Inc., Research Division Brian Skorney - Robert W. Baird & Co. Incorporated, Research Division James Condulis - Stifel, Nicolaus & Company, Incorporated, Research Division Derek Archila - Wells Fargo Securities, LLC, Research Division Yale Jen - Laidlaw & Company (UK) Ltd.
Soleno: Blockbuster Launch In Progress
Soleno Therapeutics is reassessed after a 24% drop post-VYKAT XR approval enthusiasm. SLNO now faces the critical 'danger zone' between FDA approval and successful commercialization of VYKAT XR for Prader-Willi syndrome. The company's hefty market cap and total reliance on VYKAT XR put it in 'show me' mode for investors.
Soleno Therapeutics (SLNO) Loses 26% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Soleno Therapeutics (SLNO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Soleno Therapeutics Inc. (SLNO) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
What is the earnings per share?
When is the next earnings date?
Has Soleno Therapeutics Inc. ever had a stock split?
Soleno Therapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Anish Bhatnagar CEO | NASDAQ (CM) Exchange | 834203200 CUSIP |
| US Country | 115 Employees | - Last Dividend | 26 Aug 2022 Last Split | 13 Nov 2014 IPO Date |
Overview
Soleno Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapeutics for the treatment of rare diseases. Originally founded in 1999 as Capnia, Inc., the company underwent a name change to Soleno Therapeutics, Inc. in May 2017, marking a new chapter in its journey. With its headquarters in Redwood City, California, Soleno Therapeutics is at the forefront of addressing unmet medical needs through its robust pipeline of novel treatments.
Products and Services
- Diazoxide Choline Extended-Release (DCE) Tablets
This flagship product of Soleno Therapeutics represents a significant advancement in the treatment of Prader-Willi Syndrome (PWS), a rare genetic condition. The lead candidate, a once-daily oral tablet, is currently in Phase III clinical trials, showcasing the company's commitment to providing life-changing solutions for those affected by rare diseases. DCE tablets aim to improve the quality of life for patients with PWS by offering a novel therapeutic approach.
